Edition:
United States

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

22.25USD
3:45pm EDT
Change (% chg)

$1.60 (+7.75%)
Prev Close
$20.65
Open
$20.65
Day's High
$22.40
Day's Low
$20.50
Volume
165,013
Avg. Vol
256,879
52-wk High
$33.00
52-wk Low
$13.65

ACOR.OQ

Chart for ACOR.OQ

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.65
Market Cap(Mil.): $963.52
Shares Outstanding(Mil.): 46.66
Dividend: --
Yield (%): --

Financials

  ACOR.OQ Industry Sector
P/E (TTM): -- 213.75 15.85
EPS (TTM): -1.16 -- --
ROI: -4.68 -7.93 -8.31
ROE: -7.79 -9.29 -7.95

BRIEF-Christopher James reports 5.9 pct passive stake in Acorda Therapeutics as of June 27, 2017

* Christopher M. James reports a 5.9 percent passive stake in Acorda Therapeutics Inc as of June 27, 2017- sec filing Source text (http://bit.ly/2tz6Pgg) Further company coverage:

Jul 07 2017

BRIEF-Acorda submits new drug application to U.S. Food And Drug Administration

* Acorda submits new drug application to U.S. Food And Drug Administration for inbrijatm (CVT-301, levodopa inhalation powder)

Jun 29 2017

BRIEF-Acorda Therapeutics, in May 2017, filed planned appeal of decision on 4 invalidated patents with U.S. court of appeals for federal circuit

* Acorda Therapeutics -in May 2017, filed planned appeal of decision on four invalidated patents with united states court of appeals for federal circuit

Jun 09 2017

BRIEF-Acorda Therapeutics says expects results from Tozadenant phase 3 clinical trial in Q1 2018​

* Acorda Therapeutics Inc - expects results from an ongoing tozadenant phase 3 clinical trial in q1 2018​

Jun 06 2017

BRIEF-CVT-301 phase 3 data showed significantly positive results

* CVT-301 phase 3 data showed significantly improved motor function during off periods in Parkinson’s disease

Jun 05 2017

BRIEF-Acorda Therapeutics plans to file NDA for Inbrija with U.S. FDA by end of Q2

* Acorda Therapeutics - plans to file a new drug application for inbrija with U.S. FDA by end of Q2 of 2017 Source text for Eikon: Further company coverage:

May 18 2017

BRIEF-Acorda qtrly GAAP net loss $0.41 per diluted share

* Acorda provides financial and pipeline update for first quarter 2017

Apr 27 2017

Acorda Therapeutics to cut 20 percent of workforce

Acorda Therapeutics Inc will cut nearly 20 percent of its workforce as part of a cost reduction plan, the company said on Wednesday, less than a week after losing certain patents for its multiple sclerosis (MS) drug, Ampyra.

Apr 05 2017

Acorda Therapeutics to cut 20 pct of workforce

April 5 Acorda Therapeutics Inc will cut nearly 20 percent of its workforce as part of a cost reduction plan, the company said on Wednesday, less than a week after losing certain patents for its multiple sclerosis (MS) drug, Ampyra.

Apr 05 2017

U.S. judge invalidates Acorda multiple sclerosis drug patents

A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, causing the stock to tumble 24 percent before trading was halted.

Mar 31 2017

Earnings vs. Estimates